Non-Tumorous Skin Diseases Therapeutics Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, Germany, UK, China - Size and Forecast 2024-2028

Non-Tumorous Skin Diseases Therapeutics Market 2024-2028

The global non-tumorous skin diseases therapeutics market size is estimated to grow by USD 25.22 billion, at a CAGR of 9.88% between 2023 and 2028. 

Various market players have been actively investing in the research and development (R&D) of drug products, exclusively for the treatment of non-cancerous skin diseases. Several therapeutics from companies like UCB SA (UCB), LEO Pharma AS (LEO Pharma), AbbVie, Eli Lilly and Co. (Lilly), and Galderma SA are in various stages of clinical trials for their use in the treatment of various skin diseases. The main areas of focus for market players are psoriasis and eczema. For instance, the FDA in the United States approved bimekizumab, also known as BIMZELX offered by UCB, in October 2023 for the management of moderate-to-severe plaque psoriasis in adults. A monoclonal antibody called memekizumab blocks the production of interleukin (IL)-17A and IL-17F, two important factors that contribute to chronic inflammation. Therefore, such factors are expected to drive market growth during the forecast period.

Technavio has segmented the market into Therapy Area, Route Of Administration, and Geography

• The therapy area segment includes psoriasis, eczema, acne vulgaris, and others
• The route of administration segment includes injectable, oral, and topical
• The geography segment includes key regions such as North America, Europe, Asia, and Rest of World (ROW)

It also includes an in-depth analysis of drivers, trends, and challenges. Our market analysis and report examines historical data from 2018 - 2022, besides analyzing market forecast. 

What will be the Size of the Non-Tumorous Skin Diseases Therapeutics Market During the Forecast Period?

To learn more about this report, Download Report Sample

Non-Tumorous Skin Diseases Therapeutics Market Segmentation by Therapy Area, Route Of Administration, and Geography 

Therapy Area Analysis 

Psoriasis

The market share growth by the psoriasis segment will be significant during the forecast period. Psoriasis is a highly prevalent, painful, and chronic noncommunicable skin disease. This non-cancerous skin disease speeds up the skin cells' lifestyle and causes extra skin to build up as scales and red patches on the skin's surface. Psoriasis is caused by an abnormality in the immune system, which may also impact mental health and lead to the development of comorbidities such as cardiovascular diseases and diabetes. This skin disease affects more than 125 million people around the world. 

Get a glance at the market contribution of various segments Download PDF Sample

The psoriasis segment was valued at USD 11.61 billion in 2018. The psoriasis segment held the largest market due to the increase in psoriasis research, rising disease burden and demand for psoriasis medicines in emerging economies, and the increasing use of combination therapies. Furthermore, the segment is driven by the sales of potential blockbuster drugs such as HUMIRA and TREMFYA. The segment is also projected to grow at the fastest rate during the forecast period due to the presence of a strong pipeline landscape with several promising product candidates in various stages of clinical development. Thus, the increased demand for non-cancerous disease therapeutics for psoriasis will drive the growth of the psoriasis segment in the market during the forecast period.

Route Of Administration Analysis

Injectable

Topical medications are applied directly to the affected area of the skin, offering targeted and localized therapy. They are commonly available in the form of creams, ointments, gels, lotions, or sprays. Topical treatments are relatively easy to use and allow patients to self-administer the medication, reducing the need for frequent visits to the healthcare provider. Furthermore, the increasing preference for non-invasive treatment options has fueled the growth of topical therapeutics. The development of technologically advanced formulations and the launch of new drugs will further drive the market. Additionally, the topical segment offers localized therapy, ease of use, and fewer systemic side effects. With ongoing advancements in drug delivery systems and the growing demand for non-invasive treatment options, the topical segment is poised for substantial growth in the global non-cancerous skin disease therapeutics market during the forecast period.

Oral

The oral segment plays a crucial role in the global non-cancerous skin disease therapeutics market. The oral segment has gained significant attention as a convenient and effective method of delivering therapeutics for non-cancerous skin diseases. One of the main advantages of the oral segment is its ease of administration. Compared to topical treatments, which require a precise application to affected areas, oral medications can be taken orally, making them more convenient for patients. Additionally, pharmaceutical companies and research institutions are investing in the development of innovative drugs and treatment approaches. This includes the use of targeted therapies that specifically block the molecules responsible for triggering disease symptoms. These advancements in oral therapies hold great potential for improving patient outcomes and quality of life, which, in turn, will drive market growth during the forecast period.

Regional Analysis

For more insights about the market share of various regions Download PDF Sample now!

North America is estimated to contribute 36% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. The non-cancerous skin diseases therapeutics market in North America has been witnessing significant growth over the years. Further, the non-cancerous skin diseases therapeutics market in North America is primarily driven by technological advancements and innovation in the field of dermatology. Pharmaceutical companies are investing in research and development activities to introduce novel treatment options. Additionally, a large number of awareness campaigns on the treatment of skin diseases are being organized by various associations, including the National Psoriasis Foundation (NPF), the National Eczema Association (NEA), and the PAN Foundation. Thus, such factors are expected to help the region retain its leading position in the global non-cancerous skin diseases therapeutics market during the forecast period.

Buy Full Report Now

Key Non-Tumorous Skin Diseases Therapeutics Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:

Sanofi SA: The company offers non-tumorous skin disease therapeutics such as Dupixent used for treating moderate-to-severe atopic dermatitis for children aged between 6 months to 5 years.

• AbbVie Inc.
• Amgen Inc.
• AstraZeneca Plc
• Bayer AG
• Bristol Myers Squibb Co.
• Eli Lilly and Co.
• F. Hoffmann La Roche Ltd.
• Galderma SA
• GlaxoSmithKline Plc
• Incyte Corp.
• LEO Pharma AS
• Merck KGaA
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals Inc.
• Sun Pharmaceutical Industries Ltd.
• UCB SA, Viatris Inc.
• XBiotech Inc.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Non-Tumorous Skin Diseases Therapeutics Market: Key Drivers, Trends, Challenges, and Customer Landscape

There are multiple factors influencing market growth. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. 

Key Non-Tumorous Skin Diseases Therapeutics Market Drivers

The high prevalence of skin diseases is the key factor driving market growth. The high prevalence of skin diseases globally can be a result of several factors including bacteria trapped in hair follicles and skin pores; microorganisms, parasites, or fungus living on the skin; a compromised immune system; viruses; genetic factors; exposure to irritants, allergens, or another person's infected skin; and illnesses affecting the kidneys, immune system, thyroid, and other body systems. According to the International Federation of Psoriasis Associations (IFPA), around 125 million people are currently affected by psoriasis globally. Also, more than 8 million people in the US have psoriasis.

Additionally, the large patient cohort requires multiple visits to dermatologists and numerous medications for the treatment of various skin diseases, which consequently drives the sales of dermatological therapeutics. Thus, the high prevalence of skin diseases around the world is expected to drive the growth of the global non-cancerous skin diseases therapeutics market during the forecast period.

Significant Non-Tumorous Skin Diseases Therapeutics Market Trends

Misdiagnosis of skin diseases is the primary trend shaping market growth. Within the realm of dermatology, market trends and analysis reveal a common challenge in accurately diagnosing skin diseases due to their ambiguous symptomatic presentations, often mirroring signs of various skin conditions. With the increasing prevalence of various types of skin diseases, the symptomatic signs can be quite confusing, resulting in misdiagnosis. Furthermore, patients report to the dermatologist's clinic with a previously misdiagnosed skin disease after missing a vital treatment period. Due to the increasing cases of misdiagnosed skin diseases, it is frequently recommended to visit the dermatologist's clinic if a new skin aberration is observed for more than three weeks and is continuously spreading, bleeding, growing, or modifying in any way.

Moreover, the misdiagnosis of skin diseases may have a negative impact on the global non-cancerous skin diseases therapeutics market, as dermatologists may prescribe common generic drugs for the misdiagnosed conditions instead of the expensive branded drugs indicated for the treatment of underlying severe skin diseases. Hence, the misdiagnosis of skin diseases will drive the growth of the global non-cancerous skin diseases therapeutics market during the forecast period.

Major Non-Tumorous Skin Diseases Therapeutics Market Challenges

Stringent regulatory guidelines is a challenge that affects market growth. Most clinical trials evaluating novel and innovative drugs for the treatment of several skin diseases are focused on the treatment of psoriasis, eczema indication, and atopic dermatitis. The drug development and consequent approval processes for these drugs are strictly controlled by regulatory bodies to ensure the highest levels of consistency and sterility. Safety, efficacy, drug interactions, pharmacological data, and pharmacodynamic effects are some of the main aspects inspected by these regulatory authorities. The failure of a drug to meet any of these criteria will most likely result in the manufacturer receiving a complete response letter (CRL) or complete rejection from regulatory agencies.

Furthermore, one of the major obstacles to the approval of efficacious dermatological therapeutics is the failure of the drugs to meet the appropriate endpoints needed for a successful clinical trial. Many key dermatology candidates, such as TSN2898, XEN801, and SNA-001, have faced discontinuation in the recent past due to their failure to meet primary endpoints in late-stage clinical trials. Thus, the failure of promising agents to receive regulatory approval in major Phase II and Phase III clinical studies is a key factor impeding the growth of the global non-cancerous skin diseases therapeutics market during the forecast period.

Buy Now Full Report

Key Non-Tumorous Skin Diseases Therapeutics Market Customer Landscape

The market research and growth report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Non-Tumorous Skin Diseases Therapeutics Market Customer Landscape

Segment Overview 

The non-tumorous skin diseases therapeutics market report forecasts market growth and forecasting by revenue at global, regional & country levels and provides an analysis of the latest market growth and trends from 2018 to 2028. 

• Deployment Outlook
  • Psoriasis
  • Eczema
  • Acne vulgaris
  • Others

• Route Of Administration Outlook
  • Injectable
  • Oral
  • Topical

• Region Outlook
  • North America
    • The U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Rest of Europe
  • APAC
    • China
    • India
  • Rest of World (ROW)
    • Argentina
    • Australia
    • Brazil

Non-Tumorous Skin Diseases Therapeutics Market Scope
Report Coverage	Details
Page number	176
Base year	2023
Historic period	2018-2022
Forecast period	2024-2028
Growth momentum & CAGR	Accelerate at a CAGR of 9.88%
Market Growth 2024-2028	USD 25.22 billion
Market structure	Fragmented
YoY growth 2023-2024(%)	8.95
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 36%
Key countries	US, Canada, Germany, UK, and China
Competitive landscape	Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks
Key companies profiled	AbbVie Inc., Amgen Inc., AstraZeneca Plc, Bayer AG, Bristol Myers Squibb Co., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Galderma SA, GlaxoSmithKline Plc, Incyte Corp., LEO Pharma AS, Merck KGaA, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., UCB SA, Viatris Inc., and XBiotech Inc.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download Sample PDF at your Fingertips

What are the Key Data Covered in this Non-Tumorous Skin Diseases Therapeutics Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the non-tumorous skin diseases therapeutics market growth analysis between 2024 and 2028
• Precise estimation of the non-tumorous skin diseases therapeutics market size and its contribution to the market in focus on the parent market
• Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
• Companies landscape comparing criticality of inputs and factors of differentiation
• Exclusive Matrix on companies' position and classification
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
• A thorough analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the growth of non-tumorous skin diseases therapeutics market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch